Home
Clinical Trials
A Study of Jyseleca Tablet (F...

A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants

Last Updated: 2025-05-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2040 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-02-27

Study Completion Date

2027-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to collect and evaluate the following information in relation to the safety and the efficacy of Jyseleca tablet (Filgotinib Maleate) 100 milligram (mg) and 200 mg in this post marketing setting: (1) Serious adverse events and adverse drug reactions (2) Unexpected adverse events and adverse drug reactions not reflected in precautions for use (3) Known adverse drug reactions (4) Non-serious adverse events and adverse drug reactions (5) Other safety and effectiveness related information will be evaluated in accordance with the permitted articles under the actual conditions of use in Korea.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis

NCT06625242

Rheumatoid Arthritis

ACTIVE_NOT_RECRUITING PHASE4

Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis

NCT05754710

Psoriatic Arthritis, Juvenile Polyarticular Juvenile Idiopathic Arthritis

RECRUITING

A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab

NCT04115423

Infection Rheumatoid Arthritis

UNKNOWN

A Study of Golimumab in Participants With Active Psoriatic Arthritis

NCT02181673

Arthritis, Psoriatic

COMPLETED PHASE3

Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)

NCT06222034

Juvenile Idiopathic Arthritis

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arthritis, Rheumatoid Colitis, Ulcerative

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All Participants

Korean participants who are prescribed with Jyseleca (Filgotinib Maleate) tablet 100 mg and 200 mg per approved prescribing information of Filgotinib Maleate in the post marketing setting will be enrolled and observed for up to 24 weeks or until discontinuation of treatment due to AEs or any other reason, whichever occurs first.

Non-interventional

Intervention Type OTHER

No intervention will be administered.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non-interventional

No intervention will be administered.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1\. Individuals who are being administered with Jyseleca tablet in accordance with the Korean approved label therapeutic indications.

* Korean local label therapeutic indications of Jyseleca tablet. In the following participants, Jyseleca tablet should be used only if they do not respond appropriately or are intolerant to existing treatments.
* Following:

1. Participants over 65 years of age.
2. Participants with a high cardiovascular risk.
3. Participants with malignancy.
* Rheumatoid arthritis:

1. For treatment of moderately to severely active rheumatoid arthritis in adults who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).
2. Jyseleca tablet may be used as monotherapy or in combination with methotrexate (MTX).
3. Jyseleca tablet should not be used in combination with biological DMARDs (bDMARDs) or other Janus kinase (JAK) inhibitors.
* Ulcerative colitis:

a. For treatment of moderately to severely active ulcerative colitis in adults who have an inadequate response with, lost response to, or were intolerant to either conventional therapy (corticosteroids, immunosuppressants, etc.) or biological agents.

Exclusion Criteria

1. Individuals who fall under contraindications to the administration of Jyseleca tablet in accordance with the local label by the medical judgment of the investigator.

* Contraindication for Jyseleca tablet in accordance with the Korean label:

1. Participants with hypersensitivity to the active ingredient or other ingredients of the Jyseleca tablet.
2. Participants with active infections, including serious (example, sepsis) or local infections.
3. Participants with active tuberculosis.
4. Participants with severe hepatic disorder.
5. Participants with end-stage renal disorder.
6. Participants with absolute neutrophil count (ANC) \<1\*10\^9 cells/liters (L)
7. Participants with absolute lymphocyte count (ALC) \<0.5\*10\^9 cells/L
8. Participants with hemoglobin level \<8 grams per deciliter (g/dL)
9. Pregnant or potentially pregnant women, lactating women
10. Jyseleca tablet should not be administered to participants with genetic problems such as galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption as it contains lactose.
2. Individuals who are administered Filgotinib in a clinical study other than this post marketing surveillance.
3. Individuals who are considered incompatible with participate in this surveillance by the medical judgment of the investigator.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers